Preeclampsia



Fig. 1
UtA waveforms. Spectral analysis of normal blood flow velocity waveforms obtained before pregnancy (a) and at 20 weeks (b) of gestation. In non-pregnant women and during the first half of a normal pregnancy, the flow velocity waveforms from the main UtA are characterized by a well-defined protodiastolic notch (a). End-diastolic flow increases in the main UtA and its branches during the second half of the menstrual cycle, and this increase continues as pregnancy advances (Guedes-Martins et al. 2014a, b, 2015). The presence of early diastolic notches remains relevant, particularly if bilateral, to adverse pregnancy outcome, even with normal UtA resistance values



Due to the value of UtA impedance assessments employing Doppler ultrasound, the reference ranges for the mean PI during the normal menstrual cycle (Guedes-Martins et al. 2015) and from 6 to 41 weeks in uneventful pregnancies were established and clearly revealed a general progressive gestational age-related decrement (Gómez et al. 2008; Guedes-Martins et al. 2014a). This trend has been attributed to the major changes in the placental bed that modify the properties of the UtA from a resistance vessel into a capacitance vessel (Osol and Mandala 2009).

Beyond the reference ranges for an uneventful pregnancy, a number of studies at different gestational ages have shown that UtA impedance is able to provide important predictive information about serious obstetrical disorders, such as PE. Notably, in women with gestational hypertension just before term, the incidence of elevated UtA impedance was found to be as high as 68 % and to rise to 89 % when associated with PE (Frusca et al. 2003). Other studies also observed a high incidence of abnormal UtA-PI, although at lower values, likely reflecting the different criteria for inclusion (Li et al. 2005; Meler et al. 2010).

In a group of unselected pregnant women at 22–24 weeks of gestation (Papageorghiou et al. 2001), the enhanced UtA-PI was reported to show a 69 % sensitivity for the appearance of PE with intra-uterine growth restriction (IUGR) in subsequent weeks, a value that increased to 83 % when the criteria included protodiastolic notch persistence. However, although the detection rate of PE as a result of enhanced UtA-PI was already shown to be superior to the patient’s epidemiological data detection rate (Papageorghiou et al. 2005), additional conditions had to be met. In fact, other reports indicated that the correlation between abnormal UtA impedance at 22 weeks and the establishment of PE was significant only in situations in which the fetal outcome was poor, including IUGR and preterm birth (van den Elzen et al. 1995; Aardema et al. 2004). More recently, top-decile PI values and the presence of bilateral notching were considered to have a good predictive value for an enhanced risk of stillbirth resulting from placental causes (Smith et al. 2007). As a corollary of these studies, an extensive systematic review of 74 studies including 79,547 women (Cnossen et al. 2008) with the intended purpose of evaluating the use of UtA Doppler velocimetry for the prediction of PE, concluded that UtA Doppler ultrasonography was more accurate for the prediction of PE when performed in the second trimester rather than in the first trimester. In addition, the prediction of the overall risk of PE and the risk of severe PE is significantly different in pregnant women with a low risk than in those with a high risk of developing the disease. In the group of low-risk patients, the overall risk of PE was best predicted by the presence of a second-trimester elevation of PI accompanied by UtA notching [sensitivity 23 %, specificity 99 %, positive likelihood ratio (+ve LR) 7.5, −ve LR 0.59]. Also in this low-risk group, the risk of severe PE was best predicted by either the second trimester PI (sensitivity 78 %, specificity 95 %, +ve LR 15.6, −ve LR 0.23) or bilateral notching (sensitivity 65 %, specificity 95 %, +ve LR 13.4, −ve LR 0.37). In contrast, in women at a high risk of developing PE, the overall risk of PE was best predicted by the presence of a second-trimester elevation of PI accompanied by UtA notching (sensitivity 19 %, specificity 99 %, +ve LR 21, −ve LR 0.82). Additionally, the risk of severe PE in high-risk patients was best predicted by second-trimester elevated RI (sensitivity 80 %, specificity 78 %, + ve LR 3.7, −ve LR 0.26). These findings supported the recommendation to employ PI and notching assessment in daily clinical practice (Cnossen et al. 2008).

This progressive increase in the maternal-placental blood flow during gestation is mainly due to vasodilation in part related to increased levels of 17β-estradiol, progesterone, and relaxin (Sprague et al. 2009; Vodstrcil et al. 2012). Additionally, the UtA diameter doubles in size after 20 weeks of pregnancy (Konje et al. 2001). Because blood flow within a vessel increases in proportion to the fourth power of the radius, this slight diameter increase in the UtA produces a significant blood flow capacity increase (Palmer et al. 1988; Mandala and Osol 2012) with a concomitant Doppler velocimetry increment. The downstream fall in vascular resistance leads to circumferential vessel growth, a process that nitric oxide (NO) appears to play a key role in regulating. NO is generated in the endothelium by endothelial nitric oxide synthase (eNOS) and is essential for proper endothelial function and the regulation of vascular tone. For instance, estrogen, placental growth factor (PlGF), and vascular endothelial growth factor (VEGF) augment eNOS and, consequently, NO production (Sprague et al. 2009; Mandala and Osol 2012; Grummer et al. 2009). In addition, increased soluble fms-like tyrosine kinase 1 (sFlt-1) levels inactivate and decrease circulating PlGF and VEGF concentrations and have been recognized as an important factor in PE pathogenesis (Karumanchi et al. 2005). To reverse this trend, the relative vascular insensitivity to infused angiotensin II and norepinephrine (Rosenfeld et al. 2012) also serves to increase the uteroplacental blood supply.

Abnormal UtA-PI and elevated levels of sFlt-1, reduced levels of PlGF, and an increased sFlt-1:PlGF ratio have been reported as potential predictive markers for the development of preeclampsia (Cnossen et al. 2008; Seely and Solomon 2016). However, these markers are not validated for clinical use in cases of superimposed preeclampsia.



5 Evaluation and Management of Women with Superimposed Preeclampsia


The surveillance of a pregnant woman with the diagnosis of sPE should be performed as an inpatient. This aspect is of particular importance because the failure of diagnosis or inadequate treatment of the disease is an important cause of poor obstetric outcomes, including fetal death. It is particularly important to look for signs and symptoms of severe preeclampsia, such as neurologic symptoms, epigastric or right upper quadrant pain, and nausea and vomiting (American College of Obstetricians and Gynecologists 2013).

Serial BP measurements, assessment of proteinuria from a 24-h urine collection, and laboratory evaluation (complete blood count with platelets, liver enzymes, lactic dehydrogenase, serum creatinine, and acid uric concentration) are needed. Ideally, the ACOG recommends that these laboratory results should be compared with baseline information obtained in early pregnancy. In addition, fetal growth and well-being should be assessed when sPE is suspected (American College of Obstetricians and Gynecologists 2013), and once the diagnosis of sPE is established, acute lowering of severe hypertension can be performed by oral or intravenous medications (See chapter ‘Chronic Hypertension and Pregnancy’).

For women with sPE who receive expectant management at less than 34 weeks of gestation, the American College of Obstetricians and Gynecologists recommends the administration of corticosteroids for fetal lung maturation (American College of Obstetricians and Gynecologists 2013; National Institutes of Health Consensus Development Panel 2001). Until then, there is only one randomized trial of glucocorticoids given to hypertensive women for fetal lung maturation (Amorim et al. 1999). This double-blind randomized trial enrolled 218 pregnant women with severe preeclampsia and gestational age between 26 and 34 weeks. One hundred ten women received betamethasone (12 mg administered intramuscularly, repeated after 24 h and then once a week), and 108 received placebo. The frequency of respiratory distress syndrome was significantly reduced in the corticosteroid group (23 %) compared to the placebo group (43 %), with a relative risk of 0.53 (CI95% 0.35–0. 82). The relative risks of intraventricular hemorrhage, patent ductus arteriosus, and perinatal infection were also significantly decreased in the corticosteroid group: 0.35 (CI95% 0.15–0.86), 0.27 (CI95% 0.08–0.95), and 0.39 (CI95% 0.39–0.97), respectively. There was no significant difference in the frequency of stillbirth, but the neonatal mortality rate was lower in the corticosteroid group (14 %) than in the placebo group (28 %), with a relative risk of 0.5 (CI95% 0.28–0.89). Amorim and colleagues (1999) concluded that antenatal corticosteroid therapy with betamethasone for the acceleration of fetal lung maturity is a safe and efficient treatment in patients with severe preeclampsia between 26 and 34 weeks gestation.

Although the expectant management of preterm superimposed preeclampsia among women with chronic arterial hypertension is considered a reasonable management strategy, it is associated with some maternal morbidity (Samuel et al. 2011) and with a frequency of eclampsia development estimated in the range of 0–2.5 % (Samuel et al. 2011; Chappell et al. 2008). In this context, for women with chronic hypertension and sPE with severe features, ACOG recommends the administration of intra-partum parenteral magnesium sulfate to prevent eclampsia (American College of Obstetricians and Gynecologists 2013) and immediate delivery after maternal stabilization. The ACOG task force also reinforces that for women with sPE with severe features, expectant management beyond 34 weeks of gestation is not recommended. In fact, termination of pregnancy is the only cure for preeclampsia.


6 Conclusion


The development of sPE is the most prevalent complication in pregnancy in women with chronic hypertension, and it is an important cause of bad birth outcomes, such as preterm birth, caesarean delivery, placental abruption, and fetal growth abnormalities. Because worsening chronic hypertension is managed differently from preeclampsia, it is imperative to distinguish these two entities. In addition to the fact that the diagnosis can be really difficult to achieve, there are no known tests capable of early prediction of the disease. Future research is necessary to search for improved tests to both predict and diagnose sPE.


Competing Financial Interests

The author declares no conflicts of interest.


References



Aardema MW, Saro MC, Lander M, De Wolf BT, Oosterhof H, Aarnoudse JG (2004) Second trimester Doppler ultrasound screening of the uterine arteries differentiates between subsequent normal and poor outcomes of hypertensive pregnancy: two different pathophysiological entities? Clin Sci (Lond) 106(4):377–382CrossRef


American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy (2013) Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol 122(5):1122–1131

Sep 12, 2017 | Posted by in CARDIOLOGY | Comments Off on Preeclampsia

Full access? Get Clinical Tree

Get Clinical Tree app for offline access